ReviewNature reviews. Clinical oncology2009
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Review in Nature reviews. Clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review.Oncotarget · 2016Pooled it
- KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.Oncotarget · 2015Trial
- KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients.Cancer medicine · 2023Article
- RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.Nature communications · 2022Article
- Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer.Journal of nanobiotechnology · 2022Review
- Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.Scientific reports · 2020Article
- Article
- Article
- (-)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells.Cancer cell international · 2019Article
- A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.PloS one · 2018Article
- KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.The Korean journal of internal medicine · 2017Article
- Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.Clinical lung cancer · 2016Article
- KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.Medical oncology (Northwood, London, England) · 2016Review
- Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.Oncotarget · 2015Article
- Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.Clinical lung cancer · 2015Article
- KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.Journal of experimental & clinical cancer research : CR · 2014Article
- EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.Journal of experimental & clinical cancer research : CR · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KRAS mutations may be predictive of resistance to anti-EGFR monoclonal-based therapy in patients with colorectal cancer (CRC). Screening for KRAS mutations in patients with CRC and non-small-cell lung cancer (NSCLC) may provide additional information on optimizing treatment options with targeted therapies. Only limited studies, however, have assessed the predictive value of KRAS mutations in response to conventional chemotherapy. We reviewed all relevant papers investigating the association of KRAS mutations and conventional chemotherapy-related outcome in NSCLC, CRC, and other solid tumors, both in the adjuvant and advanced settings. Our Review strongly suggests that KRAS mutations have no value in response prediction to conventional chemotherapy in NSCLC, CRC and other solid tumors. Therefore, KRAS mutations should not be used as molecular predictors of response to conventional chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.